

Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma



Erik J. Snider¹, Griselda Compres², Daniel E. Freedberg², Hossein Khiabani³, Yael R. Nobel², Stephanía Stump^{2,4}, Anne-Catrin Uhlemann^{2,4}, Charles J. Lightdale², and Julian A. Abrams²

Abstract

Background: The incidence of esophageal adenocarcinoma has risen dramatically over the past half century, and the underlying reasons are incompletely understood. Broad shifts to the upper gastrointestinal microbiome may be partly responsible. The goal of this study was to describe alterations in the esophageal microbiome that occur with progression from Barrett's esophagus to esophageal adenocarcinoma.

Methods: A case-control study was performed of patients with and without Barrett's esophagus who were scheduled to undergo upper endoscopy. Demographic, clinical, and dietary intake data were collected, and esophageal brushings were collected during the endoscopy. 16S rRNA gene sequencing was performed to characterize the microbiome.

Results: A total of 45 patients were enrolled and included in the analyses [16 controls; 14 Barrett's esophagus without dysplasia (NDBE); 6 low-grade dysplasia (LGD); 5 high-grade dysplasia (HGD); and 4 esophageal adenocarcinoma]. There was no difference in alpha diversity between

non-Barrett's esophagus and Barrett's esophagus, but there was evidence of decreased diversity in patients with esophageal adenocarcinoma as assessed by Simpson index. There was an apparent shift in composition at the transition from LGD to HGD, and patients with HGD and esophageal adenocarcinoma had decreased Firmicutes and increased Proteobacteria. In addition, patients with HGD or esophageal adenocarcinoma had increased *Enterobacteriaceae* and *Akkermansia muciniphila* and reduced *Veillonella*. In the study population, patients taking proton pump inhibitors had increased *Streptococcus* and decreased Gram-negative bacteria overall.

Conclusions: Shifts in the Barrett's esophagus-associated microbiome were observed in patients with HGD and esophageal adenocarcinoma, with increases in certain potentially pathogenic bacteria.

Impact: The microbiome may play a role in esophageal carcinogenesis.

Introduction

The incidence of esophageal adenocarcinoma has increased 10-fold since the late 1960s (1), and Barrett's esophagus incidence likely began to rise as early as the 1950s. Known modifiable risk factors for esophageal adenocarcinoma do not adequately explain these incidence trends. Gastroesophageal reflux disease (GERD) prevalence began to rise in the 1970s (2, 3), and modeling studies suggest that only a minority of esophageal adenocarcinoma cases are attributable to GERD (4). The obesity epidemic did not begin

until 1980, and obesity may only account for a small fraction of the rise in esophageal adenocarcinoma (5).

Helicobacter pylori infection is associated with a 30% to 40% reduced risk of Barrett's esophagus and esophageal adenocarcinoma (6), and *H. pylori* prevalence has plummeted since the mid-20th century (7). When present, *H. pylori* dominates the gastric microbiome, and its absence results in major shifts to gastric microbiome composition (8, 9). Thus, dramatic changes in the upper GI microbiome in western populations likely occurred at the same time that Barrett's esophagus and subsequently esophageal adenocarcinoma began to rise in incidence. Any role of the microbiome in the development of esophageal adenocarcinoma is likely complex and multifactorial, and may represent a cofactor in the development of Barrett's esophagus, the progression from Barrett's esophagus to esophageal adenocarcinoma, or both.

There is ample evidence that elements of the microbiome can directly contribute to the development of colon cancer (10). However, the role of the microbiome in the progression of Barrett's esophagus to esophageal adenocarcinoma has not been well described. In health, the esophageal microbiome is broadly similar in composition to the oral microbiome, with a high relative abundance of the phylum Firmicutes (11). Previously published data suggest that the esophageal microbiome in patients with reflux esophagitis or Barrett's esophagus is heavily

¹Department of Medicine, University of Washington School of Medicine, Seattle, Washington. ²Department of Medicine, Columbia University Irving Medical Center, New York, New York. ³Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, New Jersey. ⁴Microbiome Core Facility, Columbia University Irving Medical Center, New York, New York.

Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (<http://cebp.aacrjournals.org/>).

Corresponding Author: Julian A. Abrams, Columbia University Medical Center, 630 W. 168th Street, P&S 3-401, New York, NY 10032. Phone: 212-342-0476; Fax: 212-342-5759; E-mail: ja660@cumc.columbia.edu

Cancer Epidemiol Biomarkers Prev 2019;28:1687-93

doi: 10.1158/1055-9965.EPI-19-0008

©2019 American Association for Cancer Research.

populated with Gram-negative bacteria, which may contribute to a chronic inflammatory, proneoplastic state (12, 13). More recent analyses of esophageal adenocarcinoma surgical resections have shown that the tumor-associated microbiome demonstrates decreased microbial richness and diversity compared with non-dysplastic Barrett's esophagus and normal squamous tissue (14).

In order to understand the potential role of the microbiome in esophageal carcinogenesis, knowledge of microbiome alterations that occur along the neoplastic pathway from Barrett's esophagus to esophageal adenocarcinoma is needed. The current study aimed to elucidate shifts in the esophageal microbiome that occur in the setting of progression from Barrett's esophagus to associated dysplasia and adenocarcinoma.

Materials and Methods

Study population

This was a case-control study of patients ≥ 18 years old, enrolling subjects without or with a diagnosis of Barrett's esophagus who were scheduled to undergo upper endoscopy for clinical indications. Analysis of the salivary microbiome in these patients has been previously reported (15). Subjects were prospectively enrolled over 18 months at a single academic medical center (Columbia University Medical Center, New York, NY). Barrett's esophagus subjects had histologically confirmed Barrett's esophagus measuring ≥ 2 cm, had never received endoscopic therapy, and were taking at least once daily proton pump inhibitors (PPI) for the prior month. Barrett's esophagus subjects were categorized based on worst prior or current confirmed pathology: no dysplasia (NDBE), low-grade dysplasia (LGD), high-grade dysplasia (HGD), or esophageal adenocarcinoma. Controls were patients with no prior history of Barrett's esophagus and were included if taking at least once daily PPI or no acid suppression (PPIs or H2-receptor antagonists) for the prior month. Other details of the exclusion criteria have been described previously (15).

Demographics, clinical data, and anthropometric measures were collected. History of reflux symptoms was assessed using questionnaire (16), and dietary fat and fiber intake over the preceding 4 weeks was analyzed using a food frequency questionnaire (17, 18). All participants provided written-informed consent. The Institutional Review Board of Columbia University approved the study on February 25, 2015.

Sample collection

Details of the sample collections have been described previously (15, 19). The microbiome was sampled by brushing the squamous esophagus as well as Barrett's esophagus tissue (Barrett's esophagus patients) or gastric cardia, within 1 cm of the squamo-columnar junction (controls). Sampling of any nodules, masses, or other focal lesions was avoided, in case grossly altered topography affected bacterial colonization. Biopsies were also taken from the mid-Barrett's esophagus segment or gastric cardia for subsequent gene expression analyses.

Microbiome characterization

After DNA extraction from esophageal brushings, the V4 hyper-variable ribosomal RNA region was amplified using primers 515F and 806R (20). Sequencing of the 16S rRNA gene V4 region was performed, and sequence data were uploaded to the NCBI Sequence Read Archive (BioProjectID PRJNA517734). Greengenes was used as reference database (21). Clustering of taxonomic units

was made at 97% sequence similarity using USEARCH. The functions `classify_seqs` and `classify_otu` (both with default settings) from the mothur project (22) were used to make taxonomic assignments to operational taxonomic units (OTU). FastTree version 2.1.7 was used to generate a phylogenetic tree of the contigs (23). Using mothur and the phylogenetic tree, weighted and unweighted UniFrac distances as well as diversity indices were calculated (24).

Semiquantitative PCR (SsoAdvanced Universal SYBR Green Supermix, Bio-Rad) was also performed from esophageal brushing DNA for *Enterobacteriaceae* to further assess key findings from 16S rRNA gene sequencing analyses using previously published primer pairs (25). $\Delta\Delta C_t$ values were calculated, using as a reference the C_t value for Eubacteria for the corresponding sample. qPCR for Eubacteria represents the entire bacterial DNA in the sample; thus, the $\Delta\Delta C_t$ values were analogous to relative abundance data from 16S rRNA gene sequencing.

Statistical analyses

Continuous variables were analyzed using *t* tests and rank sum tests, and categorical variables were analyzed using the Fisher exact tests. ANOVA or Kruskal-Wallis tests were used to compare continuous variables across multiple categories. The main analyses for this study were of brushings from Barrett's mucosa (Barrett's esophagus patients) or gastric cardia (controls). Within-individual correlations were assessed between paired swabs from esophageal squamous lining and from paired swabs from Barrett's esophagus or cardia by calculating Spearman rank correlation coefficients at the genus level for all genera with non-zero read counts in both of the paired swabs. There were high correlations between paired swabs from the same site within the same individual (esophageal squamous, mean rho 0.85, SD 0.15; Barrett's esophagus or cardia, mean rho 0.86, SD 0.12). For the purpose of these analyses, the mean relative abundance for each taxon from paired swabs was calculated from each sampling site. Of note, there was also high within-individual correlation between esophageal squamous and Barrett's esophagus or cardia brushings (mean rho 0.82, SD 0.13).

Alpha diversity was assessed by observed OTUs and Shannon and Simpson indices. Pair-wise weighted and unweighted UniFrac beta diversity was calculated using functions implemented in QIIME. Nonparametric permutational MANOVA, as implemented in the FATHOM Toolbox for MATLAB, was used to compare beta-diversity measures between Barrett's esophagus versus controls and between NDBE/LGD versus HGD/esophageal adenocarcinoma groups. Principal coordinate analyses for these tests were also performed using functions implemented in the FATHOM Toolbox for MATLAB. Differentially abundant taxa between groups were identified using linear discriminant analysis effect size (LEfSe; <https://huttenhower.sph.harvard.edu/galaxy/>). Functional composition of the esophageal microbiome was assessed using predicted metabolic pathways derived by phylogenetic investigation of communities by reconstruction of unobserved states (PICRUSt) analysis (26). Analyses were performed focused on the relative abundance of Gram-negative bacteria; Gram-negative genera and species were identified using a reference list assembled by our group (Supplementary Table S1), and the relative abundances of these taxa were summed for each sample. Additional analyses were performed on relative abundance of *Streptococcus*, the most abundant genus in the esophagus; alterations in the relative abundance of this genus have been associated with a variety of esophageal conditions (13, 27, 28).

Upon visual observation of relative abundance of phyla across levels of Barrett's esophagus and associated neoplasia, it appeared that there were shifts in relative abundance of Firmicutes and Proteobacteria, the two most abundant phyla in the esophageal samples, with the transition from LGD to HGD (Supplementary Fig. S1). Thus, additional analyses were performed with Barrett's esophagus subjects categorized as NDBE/LGD or HGD/esophageal adenocarcinoma. Multivariable linear regression analyses were performed to assess for covariates independently associated with relative abundance of differentially abundant phyla and other select taxa. Full models were created including all covariates with a univariate P value < 0.10 . Variables with the highest P value and >0.15 were then sequentially removed to generate a final reduced model. Statistical significance was defined as $P < 0.05$. Analyses were performed using Stata 14.1 (StataCorp) and MATLAB (The MathWorks, Inc.).

Results

A total of 45 subjects were enrolled and had brushings collected for analysis. The characteristics of the subjects are shown in Table 1. There were 16 non-Barrett's esophagus subjects and 29 subjects with Barrett's esophagus (14 without dysplasia, 6 LGD, 5 HGD, and 4 intramucosal esophageal adenocarcinoma).

Microbiome analyses

There were no significant differences in alpha diversity comparing Barrett's esophagus with non-Barrett's esophagus patients, both in terms of richness and evenness (Supplementary Fig. S2). There was decreased diversity assessed by Simpson index, but not by Shannon index or observed OTUs, across levels of Barrett's esophagus-associated neoplasia (NDBE, LGD, HGD, and esophageal adenocarcinoma; Supplementary Fig. S3). In *post hoc* pairwise comparisons, the Simpson index in esophageal adenocarcinoma was significantly reduced compared with NDBE ($P = 0.006$), LGD ($P = 0.01$), and HGD ($P = 0.01$). None of the other pairwise comparisons were significant. On beta-diversity analyses, there was no evidence of significant clustering comparing Barrett's esophagus versus controls (Supplementary Fig. S4).

The most abundant phyla in the samples from Barrett's esophagus and gastric cardia were Firmicutes (46.2%), Proteobacteria (22.9%), Bacteroidetes (19.6%), Actinobacteria (5.6%), and Fusobacteria (5.1%). Barrett's esophagus subjects had significantly reduced relative abundance of Bacteroidetes compared with controls (16.3% vs. 25.5%, $P = 0.04$), although there was no association after adjusting for patient characteristics (Supplementary Table S2).

There were no overall differences in relative abundance of phyla across levels of Barrett's esophagus-associated neoplasia. However, upon visual inspection of the results, it appeared that there was a shift in composition with regard to Firmicutes and Proteobacteria, the two predominant phyla, with the transition from LGD to HGD (Supplementary Fig. S1). Thus, subsequent analyses were performed with Barrett's esophagus subjects categorized as (NDBE or LGD) and (HGD or esophageal adenocarcinoma). Compared with NDBE/LGD, subjects with HGD/esophageal adenocarcinoma had decreased relative abundance of Firmicutes (38.3% vs. 55.0%, $P = 0.04$) and increased relative abundance of Proteobacteria (32.1% vs. 17.7%, $P = 0.04$; Fig. 1). In multivariable analyses, HGD/esophageal adenocarcinoma remained

Table 1. Characteristics of patients who underwent upper endoscopy and had microbiome analyses, comparing those without with those with Barrett's esophagus

	Non-Barrett's esophagus (n = 16)	Barrett's esophagus (n = 29)	P
Age, mean (SD)	60.1 (14.9)	63.6 (11.7)	0.39
Sex, male	9 (56%)	25 (86%)	0.04
WHR, mean (SD)	0.95 (0.08)	0.97 (0.05)	0.37
GERD	10 (63%)	27 (93%)	0.02
Ever smoker	7 (44%)	19 (66%)	0.21
PPI use	6 (38%)	29 (100%)	<0.001
Aspirin use	3 (19%)	11 (38%)	0.31
Dietary fiber ^a , grams per day; mean (SD)	15.2 (5.3)	16.5 (4.5)	0.42
Dietary fat ^a , % daily calories; mean (SD)	33.6 (2.3)	34.3 (3.2)	0.46

Abbreviation: WHR, waist-to-hip ratio.

^aDietary data missing in 1 subject.

independently associated both with increased Firmicutes ($P = 0.03$) and decreased Proteobacteria ($P = 0.01$; Supplementary Table S2). On beta-diversity analyses, there was no evidence of significant clustering comparing HGD/esophageal adenocarcinoma versus NDBE/LGD (Supplementary Fig. S4).

Taxonomic differences

As compared with controls, subjects with Barrett's esophagus had increased relative abundance of *Sphingomonas* and an unclassified species of *Campylobacter*. Non-Barrett's esophagus subjects had increased relative abundance of various taxa including *Prevotella pallens*, *Porphyromonas endodontalis*, and *Aggregatibacter segnis* (Supplementary Table S3). Based on the observations that there was a shift with transition from LGD to HGD at the phylum level, additional differences in relative abundance of taxa were assessed by LEfSe with subjects again categorized as NDBE/LGD and HGD/esophageal adenocarcinoma (Fig. 2A). Patients with NDBE/LGD had significantly increased *Veillonella*. Several taxa were increased in the HGD/esophageal adenocarcinoma subjects, notably in *Enterobacteriaceae* and *Verrucomicrobiaceae*, specifically *Akkermansia muciniphila* (Fig. 2B).




Figure 1.

Relative abundance of the major phyla comparing subjects with no dysplasia or LGD with those with HGD or esophageal adenocarcinoma (EAC). Compared with NDBE/LGD subjects, those with HGD or EAC had decreased Firmicutes ($P = 0.04$) and increased Proteobacteria ($P = 0.04$).




Figure 2.
A, Cladogram from LEfSe analyses of differentially abundant taxa comparing Barrett's esophagus patients without dysplasia (NDBE) or LGD versus HGD or esophageal adenocarcinoma (EAC). **B**, Subjects with HGD or EAC had reduced relative abundance of *Veillonella* (left) and had increased proportion of samples with presence of the other differentially abundant taxa (right), which were relatively rare. (Presence defined as having any reads, except for *Enterobacteriaceae*, which was defined as relative abundance > 0.1%.)

As members of *Enterobacteriaceae* can promote gut inflammation and neoplasia, the data on this family were examined in greater detail. Compared with NDBE/LGD, patients with HGD/esophageal adenocarcinoma were more likely to be smokers ($P = 0.03$) and had higher dietary fat intake ($P = 0.05$). After adjusting for these two factors, HGD/esophageal adenocarcinoma remained significantly associated with the relative abundance of *Enterobacteriaceae* ($P = 0.02$; Supplementary Table S2). Two subjects had very high relative abundance of *Enterobacteriaceae*: one of these had HGD and a relative abundance of 38.3%, and one had intramucosal esophageal adenocarcinoma and a relative abundance of 30.4%. These findings were replicated in the esophageal squamous brushings, where these two subjects again had the highest relative abundance of *Enterobacteriaceae* in the study population. For each of these subjects, a single distinct OTU drove the high relative abundance. On further evaluation of these OTUs using NCBI BLAST, one matched predominantly to species in the genera *Klebsiella* and *Enterobacter*, and the other matched to species in genera including *Escherichia* and *Shigella*.

Esophageal and cardia biopsies were then analyzed by qPCR to assess whether they harbored differences compared with brushings in relative abundance of *Enterobacteriaceae*. There was

no significant difference by qPCR comparing patients with NDBE/LGD and HGD/esophageal adenocarcinoma (median $\Delta\Delta Ct$ 12.5 vs. 12.8, respectively; $P = 0.57$).

Gram-negative bacteria

In brushings, the mean relative abundance of Gram-negative bacteria in all of the subjects was 54.7% (SD 23.0). There was no significant difference in the relative abundance of Gram-negative bacteria comparing non-Barrett's esophagus controls with Barrett's esophagus subjects (61.6% vs. 50.9%, $P = 0.14$). There were also no significant alterations in the relative abundance of Gram-negative bacteria across levels of Barrett's esophagus-associated neoplasia (ANOVA, $P = 0.66$). In the entire study population (Barrett's esophagus and non-Barrett's esophagus), PPI users had decreased relative abundance of Gram-negative bacteria compared with PPI nonusers (51.1% vs. 67.3%; $P = 0.05$; Fig. 3A).

Streptococcus

The mean relative abundance of *Streptococcus* in the study population was 32.6% (SD 20.9%). There was no significant difference in the relative abundance of *Streptococcus* comparing Barrett's esophagus patients with non-Barrett's esophagus




Figure 3.

Compared with controls not taking PPIs, patients taking PPIs had (A) reduced relative abundance of Gram-negative bacteria ($P = 0.05$) and (B) increased relative abundance of *Streptococcus* ($P = 0.03$).

controls (35.7% vs. 26.9%, $P = 0.18$) and no significant overall alteration in the relative abundance of *Streptococcus* across levels of Barrett's esophagus-related neoplasia (ANOVA $P = 0.51$). With regard to PPI use, all subjects (Barrett's esophagus and non-Barrett's esophagus) on PPIs had greater relative abundance of *Streptococcus* compared with controls not on PPIs (36.2% vs. 19.9%, $P = 0.03$; Fig. 3B).

Functional profiling

PICRUSt analyses were performed to assess for functional alterations to the esophageal microbiome. Several gene pathways were significantly altered comparing patients with Barrett's esophagus with non-Barrett's esophagus controls (Supplementary Fig. S5A). Controls had increased RNA degradation and vitamin B6 metabolism, whereas Barrett's esophagus patients had increased glycerolipid metabolism. Compared with patients with NDBE or LGD, those with HGD or esophageal adenocarcinoma exhibited increased glycerophospholipid metabolism and decreased other glycan degradation (Supplementary Fig. S5B).

Discussion

In the current study, we assessed the Barrett's esophagus microbiome with progression to dysplasia and adenocarcinoma. We observed a shift in composition with progression, notably at the

transition from LGD to HGD. This was manifested by significant clustering in beta-diversity analyses, as well as alterations to the two predominant phyla, with reductions in Firmicutes and increases in Proteobacteria.

There are little previous data describing esophageal microbiome changes that occur in the development of esophageal adenocarcinoma. Elliott and colleagues reported microbiome alterations comparing esophageal squamous samples from non-Barrett's esophagus controls, Barrett's samples from patients without dysplasia, and tumor tissue from patients with esophageal adenocarcinoma (14). The authors noted that esophageal adenocarcinoma tumors had decreased alpha diversity compared with Barrett's esophagus, and in the present study, there was some evidence of a decline in diversity with progression. However, many of the specific taxonomic alterations were distinct. This may be explained in part by the fact that the esophageal adenocarcinoma tumor-microbiome was analyzed in this prior study (14), whereas in the current study, sampling was performed only of normal appearing Barrett's mucosa, avoiding any nodules or lesions, in patients with esophageal adenocarcinoma. Also in the current study, there were high within-individual correlations between squamous and Barrett's esophagus or cardia brushings, but the across-group alterations were less marked in squamous as compared with Barrett's esophagus or cardia (data not shown). Finally, the esophageal adenocarcinoma subjects in the current

study all had very early lesions (T1a), and thus microbiome alterations in these patients would not have been caused by stasis due to tumor obstruction.

The increased relative abundance of *Enterobacteriaceae* in esophageal brushings from patients with HGD and esophageal adenocarcinoma has potential biological significance. Certain species within *Enterobacteriaceae* harbor the *pks* genomic island and can produce colibactin, a genotoxin that induces DNA damage (29). Colibactin-producing *Escherichia coli* promote tumor growth in xenograft mouse models (30), modify the tumor microenvironment (31), and have been found in high abundance in colonic biofilms in patients with familial adenomatous polyposis (32). Members of the family *Enterobacteriaceae* have also been implicated in gut inflammation in inflammatory bowel disease (33–35). Thus, it is plausible that increased levels of *Enterobacteriaceae* in Barrett's esophagus may promote progression to esophageal adenocarcinoma, either directly via colibactin or other bacterial products or indirectly by triggering an immune response and local inflammation.

Interestingly, the *Enterobacteriaceae* findings from 16S analyses of esophageal brushings were not replicated by qPCR of esophageal biopsies. However, the two subjects with high relative abundance of *Enterobacteriaceae* had similar findings in the squamous esophagus, in line with prior work demonstrating that there is little within-individual variability in the microbiome in the squamous and Barrett's lining in patients with Barrett's esophagus (36). Further, our group previously showed that patients with HGD or esophageal adenocarcinoma have increased *Enterobacteriaceae* in saliva, and that there is strong within-individual correlation between the salivary and esophageal microbiome (15). Thus, possible explanations for the discrepant findings are that esophageal brushings are superior to biopsies for microbiome assessment, as previously reported by Gall and colleagues (36), and that *Enterobacteriaceae* may reside predominantly within the esophageal biofilm rather than within the mucosa (37).

The increased relative abundance of *A. muciniphila* in subjects with HGD or esophageal adenocarcinoma was also notable. In the colon, *A. muciniphila* has been associated with many beneficial effects related to obesity and metabolic syndrome (38). However, depending on the context, this species also can degrade mucins and thin the mucus layer (39), potentially leading to increased interaction between pathobionts and the underlying epithelium. In this fashion, the presence of *A. muciniphila* could conceivably lead to increased Barrett's tissue inflammation and promote progression to esophageal adenocarcinoma.

Yang and colleagues previously described a microbiome associated with reflux esophagitis and Barrett's esophagus that was characterized by decreased relative abundance of *Streptococcus* and increased relative abundance of Gram-negative bacteria (13). In the current study, there were no differences in relative abundance of *Streptococcus* or in overall Gram-negative bacteria comparing nondysplastic Barrett's esophagus with controls (data not shown) or with progression from Barrett's esophagus to esophageal adenocarcinoma. However, controls not taking PPIs had increased Gram-negative bacteria and decreased *Streptococcus* compared with subjects on PPIs, and our group has previously demonstrated that PPIs cause significant increases in *Streptococcus* in the distal gut (40). If Gram-negative bacteria in the esophagus promote chronic inflammation and increase the risk of Barrett's esophagus and esophageal adenocarcinoma (12), then PPIs may provide a chemoprotective effect by reducing overall levels of

Gram-negative bacteria. However, the PPI results from the current study should be interpreted with caution, as the PPI users were a mix of Barrett's esophagus and non-Barrett's esophagus patients.

The current study has several strengths. There were patients from all stages of Barrett's esophagus-associated neoplasia, which permitted the ascertainment of microbiome shifts prior to the development of esophageal adenocarcinoma. During the endoscopy, only flat Barrett's esophagus tissue was sampled, avoiding lesions so as to minimize confounding by the presence of bacteria that may have been mere colonizers due to an altered tumor macro- and microenvironment. Care was taken with regard to exclusion criteria to minimize the effects of certain factors on the microbiome such as antibiotics and immunosuppressants. Detailed clinical information and dietary intake data were recorded and assessed in the analyses.

There were also certain limitations. The sample size was relatively small, and the study may have been underpowered to detect additional important microbiome alterations associated with neoplastic progression in Barrett's esophagus. The current study describes associations with various stages of Barrett's esophagus neoplasia but no information on causative effects on progression. However, the findings provide key hypothesis-generating data for follow-up functional studies.

In conclusion, there were pronounced shifts in the microbiome in Barrett's esophagus associated with progression to esophageal adenocarcinoma, particularly at the transition from LGD to HGD. Notably, patients with HGD and esophageal adenocarcinoma had increased relative abundance of *Enterobacteriaceae*, and members of this family have been implicated in gut inflammation and carcinogenesis. Further studies are indicated to identify specific bacteria that may promote the development of esophageal adenocarcinoma, and also whether therapies targeting the microbiome can be developed to modify the risk of esophageal adenocarcinoma.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: E.J. Snider, Y.R. Nobel, J.A. Abrams

Development of methodology: E.J. Snider, D.E. Freedberg, H. Khiabani, S. Stump, J.A. Abrams

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): E.J. Snider, D.E. Freedberg, S. Stump, C.J. Lightdale, J.A. Abrams

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E.J. Snider, H. Khiabani, A.-C. Uhlemann, C.J. Lightdale, J.A. Abrams

Writing, review, and/or revision of the manuscript: E.J. Snider, D.E. Freedberg, H. Khiabani, Y.R. Nobel, A.-C. Uhlemann, C.J. Lightdale, J.A. Abrams

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): E.J. Snider, S. Stump

Study supervision: J.A. Abrams

Other (research coordinator): G. Compres

Acknowledgments

The authors were supported in part by a Columbia Physician's and Surgeon's Dean's Research Fellowship (E.J. Snider), a Career Development Award from NIDDK (K23 DK111847; D.E. Freedberg), a U54 award from NCI (U54 CA163004; J.A. Abrams), a R01 from NIAID (AI116939; A.-C. Uhlemann), and the Price Family Foundation (J.A. Abrams).

The authors would like to acknowledge the New York Genome Center for performing the 16S rRNA gene sequencing on the samples collected as part of this study. The authors would also like to acknowledge Nora C. Toussaint (ETH

Zurich, NEXUS Personalized Health Technologies; New York Genome Center) for assistance with processing and analyses of the sequencing data.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked

advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 2, 2019; revised April 17, 2019; accepted July 10, 2019; published first August 29, 2019.

References

- Abrams JA, Sharaiha RZ, Gonsalves L, Lightdale CJ, Neugut AI. Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940-2007. *Cancer Epidemiol Biomarkers Prev* 2011;20:183-6.
- el-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. *Gut* 1998;43:327-33.
- Friedenberg FK, Hanlon A, Vanar V, Nehemia D, Mekapati J, Nelson DB, et al. Trends in gastroesophageal reflux disease as measured by the National Ambulatory Medical Care Survey. *Dig Dis Sci* 2010;55:1911-7.
- Hazelton WD, Curtius K, Inadomi JM, Vaughan TL, Meza R, Rubenstein JH, et al. The role of gastroesophageal reflux and other factors during progression to esophageal adenocarcinoma. *Cancer Epidemiol Biomarkers Prev* 2015;24:1012-23.
- Kong CY, Nattinger KJ, Hayeck TJ, Omer ZB, Wang YC, Spechler SJ, et al. The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model. *Cancer Epidemiol Biomarkers Prev* 2011;20:2450-6.
- Islami F, Kamangar F. *Helicobacter pylori* and esophageal cancer risk: a meta-analysis. *Cancer Prev Res* 2008;1:329-38.
- Banatvala N, Mayo K, Megraud F, Jennings R, Deeks JJ, Feldman RA. The cohort effect and *Helicobacter pylori*. *J Infect Dis* 1993;168:219-21.
- Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, Francois F, et al. Molecular analysis of the bacterial microbiota in the human stomach. *Proc Natl Acad Sci U S A* 2006;103:732-7.
- Abreu MT, Peek RM Jr. Gastrointestinal malignancy and the microbiome. *Gastroenterology* 2014;146:1534-46.e3.
- Brennan CA, Garrett WS. Gut microbiota, inflammation, and colorectal cancer. *Annu Rev Microbiol* 2016;70:395-411.
- Pei Z, Bini EJ, Yang L, Zhou M, Francois F, Blaser MJ. Bacterial biota in the human distal esophagus. *Proc Natl Acad Sci U S A* 2004;101:4250-5.
- Yang L, Francois F, Pei Z. Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. *Clin Cancer Res* 2012;18:2138-44.
- Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. *Gastroenterology* 2009;137:588-97.
- Elliott DRF, Walker AW, O'Donovan M, Parkhill J, Fitzgerald RC. A non-endoscopic device to sample the oesophageal microbiota: a case-control study. *Lancet Gastroenterol Hepatol* 2017;2:32-42.
- Snider EJ, Compres G, Freedberg DE, Giddins MJ, Khiabani H, Lightdale CJ, et al. Barrett's esophagus is associated with a distinct oral microbiome. *Clin Transl Gastroenterol* 2018;9:135.
- Locke GR, Talley NJ, Weaver AL, Zinsmeister AR. A new questionnaire for gastroesophageal reflux disease. *Mayo Clin Proc* 1994;69:539-47.
- Thompson FE, Midthune D, Subar AF, Kahle LL, Schatzkin A, Kipnis V. Performance of a short tool to assess dietary intakes of fruits and vegetables, percentage energy from fat and fibre. *Public Health Nutr* 2004;7:1097-105.
- Thompson FE, Midthune D, Subar AF, McNeel T, Berrigan D, Kipnis V. Dietary intake estimates in the National Health Interview Survey, 2000: methodology, results, and interpretation. *J Am Diet Assoc* 2005;105:352-63; quiz 487.
- Nobel YR, Snider EJ, Compres G, Freedberg DE, Khiabani H, Lightdale CJ, et al. Increasing dietary fiber intake is associated with a distinct esophageal microbiome. *Clin Transl Gastroenterol* 2018;9:199.
- Nossa CW, Oberdorf WE, Yang L, Aas JA, Paster BJ, Desantis TZ, et al. Design of 16S rRNA gene primers for 454 pyrosequencing of the human foregut microbiome. *World J Gastroenterol* 2010;16:4135-44.
- Edgar RC. Search and clustering orders of magnitude faster than BLAST. *Bioinformatics* 2010;26:2460-1.
- Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. *Appl Environ Microbiol* 2009;75:7537-41.
- Price MN, Dehal PS, Arkin AP. FastTree 2—approximately maximum-likelihood trees for large alignments. *PLoS One* 2010;5:e9490.
- Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. *Appl Environ Microbiol* 2005;71:8228-35.
- Fan D, Coughlin LA, Neubauer MM, Kim J, Kim MS, Zhan X, et al. Activation of HIF-1 α and LL-37 by commensal bacteria inhibits *Candida albicans* colonization. *Nat Med* 2015;21:808-14.
- Langille MG, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. *Nat Biotechnol* 2013;31:814-21.
- Harris JK, Fang R, Wagner BD, Choe HN, Kelly CJ, Schroeder S, et al. Esophageal microbiome in eosinophilic esophagitis. *PLoS One* 2015;10:e0128346.
- Benitez AJ, Hoffmann C, Muir AB, Dods KK, Spergel JM, Bushman FD, et al. Inflammation-associated microbiota in pediatric eosinophilic esophagitis. *Microbiome* 2015;3:23.
- Bossuet-Greif N, Vignard J, Taieb F, Mirey G, Dubois D, Petit C, et al. The colibactin genotoxin generates DNA interstrand cross-links in infected cells. *mBio* 2018;9. pii: e02393-17.
- Cougnoux A, Dalmasso G, Martinez R, Buc E, Delmas J, Gibold L, et al. Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. *Gut* 2014;63:1932-42.
- Dalmasso G, Cougnoux A, Delmas J, Darfeuille-Michaud A, Bonnet R. The bacterial genotoxin colibactin promotes colon tumor growth by modifying the tumor microenvironment. *Gut Microbes* 2014;5:675-80.
- Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. *Science* 2018;359:592-7.
- Wright EK, Kamm MA, Teo SM, Inouye M, Wagner J, Kirkwood CD. Recent advances in characterizing the gastrointestinal microbiome in Crohn's disease: a systematic review. *Inflamm Bowel Dis* 2015;21:1219-28.
- Lewis JD, Chen EZ, Baldassano RN, Otley AR, Griffiths AM, Lee D, et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn's disease. *Cell Host Microbe* 2015;18:489-500.
- Garrett WS, Gallini CA, Yatsunenko T, Michaud M, DuBois A, Delaney ML, et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. *Cell Host Microbe* 2010;8:292-300.
- Gall A, Fero J, McCoy C, Claywell BC, Sanchez CA, Blount PL, et al. Bacterial composition of the human upper gastrointestinal tract microbiome is dynamic and associated with genomic instability in a Barrett's esophagus cohort. *PLoS One* 2015;10:e0129055.
- Blackett KL, Siddhi SS, Cleary S, Steed H, Miller MH, Macfarlane S, et al. Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett's and oesophageal carcinoma: association or causality? *Aliment Pharmacol Ther* 2013;37:1084-92.
- Derrien M, Belzer C, de Vos WM. *Akkermansia muciniphila* and its role in regulating host functions. *Microb Pathog* 2017;106:171-81.
- Shono Y, Docampo MD, Peled JU, Perobelli SM, Velardi E, Tsai JJ, et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. *Sci Transl Med* 2016;8:339ra71.
- Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. *Gastroenterology* 2015;149:883-5e9.